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Dear Editor, 
Betulinic acid (3β-hydroxy-lup-20(29)-en-28-oic acid, BA), a pentacyclic lupane-type 
triterpene, is widely distributed in the plant kingdom (Mukherjee et al., 2006; Fulda, 2008). 
Johann Tobias Lowitz isolated the reduced form of BA from plants in 1788 and found that it 
was a prominent outer-bark constituent in white-barked birch trees (Bag and Dash, 2011). BA 
has a wide range of biological and medicinal properties, including anti-human immunodefi-
ciency virus (HIV), antibacterial, antimalarial, anti-inflammatory, anthelmintic, antinocicep-
tive, anti-herpes simplex viruses-1 (HSV-1), immune-modulatory, antiangiogenic, and anti-
cancer activity (Yogeeswari and Sriram, 2005; Gheorgheosu et al, 2014). Furthermore, the an-
ti-tumor activity of BA can help overcome resistance by inducing apoptosis in a variety of 
human cancers.  
Semi-synthetic derivatives of natural plant products continue to play an important role in 
drug discovery and development (Pan et al., 2010). To improve the potency of BA, many de-
rivatives have been synthesized and evaluated for biological/medicinal applications (Jonnala-
gadda et al., 2013; Csuk, 2014). Because of its range of biological properties, BA has attracted 
much attention in recent years in the pharmaceutical industry. Here, we summarize key recent 
studies performed to evaluate the biological and pharmacological activities of BA and its de-
rivatives (Table 1).  
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Table 1: Recent studies on betulinic acid and its biological and pharmacological activities 
Key message Reference 
BA protects the lungs against inflammation and could be a potential modu-
lator of inflammation in sepsis-induced acute lung injury. 
Lingaraju et al., 2015 
BA induces HeLa cell apoptosis by triggering both the endoplasmic reticu-
lum pathway and the reactive oxygen species (ROS)-mediated mitochon-
drial pathway. 
Xu et al., 2014 
BA mediates the anti-estrogenic effects of Proteus vulgaris; this suggests 
its potential use as a therapeutic agent in estrogen-dependent tumors.  
Kim et al., 2014 
BA dose-dependently inhibits proliferation and induces apoptosis in neuro-
blastoma and melanoma cell line apoptosis.  
Tiwari et al, 2014 
BA reduces lactase dehydrogenase (LDH) and creatine kinase (CK) re-
lease, prevents cardiomyocyte apoptosis, and alleviates the extent of myo-
cardial ischemia/reperfusion injury. 
Xia et al., 2014 
Combination of BA with cyclodextrin treatment enhances anti-proliferative 
activity and aids in preventing in vivo tumor development. 
Soica et al., 2014 
The betulin (BE) derivative BT06 and BA derivative AB13 may be promis-
ing alternatives leishmaniasis therapies, particularly in combination with 
miltefosine. 
Sousa et al., 2014 
BA derived from Vitis amurensis root plays a novel role in melanogenesis. 
This finding has advanced our understanding of cosmetic therapy to reduce 
skin hyperpigmentation. 
Jin et al., 2014 
Spray drying BA is a superior alternative formulation that significantly in-
creases BA oral bioavailability and enhances anticancer efficacy. 
Godugu et al., 2014 
BA may prevent bone loss in patients with bone metastases and cancer 
treatment-induced estrogen deficiency. 
Park et al., 2014 
BA may exert hepatoprotective effects by increasing antioxidant capacity, 
through the improvement of the tissue redox system, maintenance of the 
antioxidant system, and decreased lipid peroxidation in the liver.  
Yi et al., 2014 
BA regulates glycemia through classical insulin signaling by stimulating 
GLUT4 synthesis and translocation. Additionally, it does not cause hyper-
calcemia, which is highly significant from a drug-discovery perspective. 
Castro et al., 2014 
BA has thyroid-enhancing potential by lowering thyroid-stimulating hor-
mone levels and reducing thyroid tissue damage, thereby minimizing the 
symptoms of hypothyroidism when used anaphylactically in rats. 
Afzal et al., 2014 
BA induces eryptosis/erythroptosis in human erythrocytes through Ca2+ 
loading and membrane permeabilization. 
Gao et al., 2014 
A novel mechanism for BA-mediated ATP-binding cassette transporter A1 
(ABCA1) expression has been proposed, which may provide new methods 
to modulate vascular inflammation and atherosclerosis.  
Zhao et al., 2013 
Topomer CoMFA studies on 37 BA and BE derivatives confirmed their in 
vitro anticancer activity (reported as IC50 values) in HT29 human colon 
cancer cells.  
Ding et al., 2013 
Several novel 2,4-dinitrophenylhydrazone BA derivatives were prepared by 
chemical and biotransformation methods using fungi and carrot cells. Some 
compounds showed significant cytotoxicity and selectivity against tumor 
cell lines. 
Baratto et al., 2013 
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Table 1 (cont.): Recent studies on betulinic acid and its biological and pharmacological activities 
Key message Reference 
Histopathological analyses of tumors revealed decreased angiogenesis, 
proliferation, and invasion in BA-treated animals. This is one of the first 
studies demonstrating the in vivo antitumor activity of BA in MCF-7 breast 
cancer tumors in nude mice. 
Damle et al., 2013 
Lamin B1, which plays a crucial role in pancreatic cancer, was significantly 
downregulated by BA treatment in pancreatic cancer cells in vitro and in 
xenograft models. 
Li et al., 2013 
BA or BE may ameliorate acute ethanol-induced fatty liver via toll-like re-
ceptor 4 (TLR4) and signal transducer and activator of transcription 3 
(STAT3) in vivo and in vitro, suggesting it may be a promising agent for 
ethanol-induced fatty liver therapies. 
Wan et al., 2013 
BA modulates the activity of xenobiotic and antioxidative enzymes with pu-
tative roles in cancer initiation and proliferation. 
Kaur and Arora, 2013 
BA ameliorates intracellular lipid accumulation in liver cells, and may be a 
potential therapeutic for the prevention of fatty liver disease. 
Quan et al., 2013 
BA inhibits deubiquitinases and induces apoptotic cell death in prostate 
cancer, but not normal, cells and tissues. Thus, it may be an effective, non-
toxic, and clinically selective chemotherapeutic. 
Reiner et al., 2013 
BA prevents endothelium-dependent relaxation (EDR) impairment in rat 
aortas exposed to exogenous superoxide anion, which may closely relate 
to oxidative stress reduction and endothelial nitric oxide synthase (eNOS)-
nitric oxide (NO) pathway activation. 
Qian et al., 2012 
BA induces apoptosis and blocks autophagic flux in KM3 cells. Both 
caspase 3 activation and autophagic flux inhibition contribute to BA-
mediated apoptosis.  
Yang et al., 2012 
BA may exert its anti-tumor effects by inducing tumor cell apoptosis. This 
process may also improve the immune response. 
Wang et al., 2012 
BA may serve as an antithrombotic compound via antiplatelet activity. The 
antiplatelet effect of BA has been suggested to be similar to that prostacy-
clin (PGI2) receptor agonists; however, this requires further investigation.  
Tzakos et al., 2012 
BA may be a potent and effective anticancer agent in nasopharyngeal car-
cinoma (NPG). Further exploration of the mechanism of action could yield 
novel breakthroughs in anticancer drug discovery.  
Liu and Luo, 2012 
BA has anti-inflammatory and antioxidant properties that protect the lung 
against the deleterious effects of lipopolysaccharide. 
Nader and Baraka, 
2012 
BA significantly inhibits fibrosis by modulating the TLR4/myeloid differentia-
tion factor 88 (MyD88)/nuclear factor (NF)-κB signaling pathway. 
Wan et al., 2012 
BA may have anti-obesity effects by directly inhibiting pancreatic lipase. 
This may prevent the absorption of lipids from the small intestine. Further, 
BA may further accelerate fat mobilization by enhancing lipolysis in adipose 
tissues. 
Kim et al., 2012 
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